echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Lymphoma Myeloma Leuk: CAR-T therapy can be used to treat patients with relapsed/refractory B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

    Clin Lymphoma Myeloma Leuk: CAR-T therapy can be used to treat patients with relapsed/refractory B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

    • Last Update: 2021-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Currently, in patients with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation (Allo-HSCT), there is a lack of safe and effective rescue therapy.


    stem cell

    From September 2017 to October 2019, the study included 11 patients with B-cell acute lymphoblastic leukemia who relapsed after Allo-HSCT treatment.


     

    The results showed that 8 patients (72.


    In summary, the results of this prospective study show that allogeneic donor-derived anti-CD19 CAR T cell therapy is a safe and effective rescue plan, suitable for relapsed/refractory B-cell acute lymphocytes after allogeneic hematopoietic stem cell transplantation Patients with leukemia.


     

    Original source:

     

    Jingsheng Hua, et al.


    ncbi.
    nlm.
    nih.
    gov/32507386/" target="_blank" rel="noopener">Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed / Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.